Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Capromab pendetide. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Capromab pendetide. |
| Estrone | Estrone may increase the thrombogenic activities of Capromab pendetide. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Capromab pendetide. |
| Estriol | Estriol may increase the thrombogenic activities of Capromab pendetide. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Capromab pendetide. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Capromab pendetide. |
| Tibolone | Tibolone may increase the thrombogenic activities of Capromab pendetide. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Capromab pendetide. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Capromab pendetide. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Capromab pendetide. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Capromab pendetide. |
| Zeranol | Zeranol may increase the thrombogenic activities of Capromab pendetide. |
| Equol | Equol may increase the thrombogenic activities of Capromab pendetide. |
| Promestriene | Promestriene may increase the thrombogenic activities of Capromab pendetide. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Capromab pendetide. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Capromab pendetide. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Capromab pendetide. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Capromab pendetide. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Capromab pendetide. |
| Formononetin | Formononetin may increase the thrombogenic activities of Capromab pendetide. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Capromab pendetide. |
| Estradiol | Estradiol may increase the thrombogenic activities of Capromab pendetide. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Capromab pendetide. |
| Mestranol | Mestranol may increase the thrombogenic activities of Capromab pendetide. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Capromab pendetide. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Capromab pendetide. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Capromab pendetide. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Capromab pendetide. |
| Estetrol | Estetrol may increase the thrombogenic activities of Capromab pendetide. |
| Leuprolide | Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Goserelin | Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Gonadorelin | Gonadorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Nafarelin | Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Buserelin | Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Histrelin | Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Triptorelin | Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Deslorelin | Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Danazol | Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Elagolix | Elagolix may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Gestrinone | Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Flutamide | Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Nilutamide | Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Bicalutamide | Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Enzalutamide | Enzalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Apalutamide | Apalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Darolutamide | Darolutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Cyproterone acetate | Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Chlormadinone | Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Relugolix | Relugolix may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Chlormadinone acetate | Chlormadinone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Capromab pendetide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Capromab pendetide. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Capromab pendetide. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Capromab pendetide. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Capromab pendetide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Capromab pendetide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Capromab pendetide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Capromab pendetide. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Capromab pendetide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Capromab pendetide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Natalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bevacizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Technetium Tc-99m arcitumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Panitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ranibizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Enokizumab. |